Meridian Bioscience (NASDAQ:VIVO) reported its Q1 earnings results on Friday, February 4, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Meridian Bioscience beat estimated earnings by 40.0%, reporting an EPS of $0.35 versus an estimate of $0.25, which surprised analysts.
Revenue was up $4.58 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.03, which was followed by a 7.19% increase in the share price the next day.
Here's a look at Meridian Bioscience's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | 0.20 | 0.31 | 0.48 | 0.42 |
| EPS Actual | 0.23 | 0.22 | 0.56 | 0.65 |
| Revenue Estimate | 68.40M | 77.22M | 84.48M | 83.89M |
| Revenue Actual | 76.20M | 63.51M | 85.26M | 92.92M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Meridian Bioscience management provided guidance for their next quarter, expecting earnings between $1.1 and $1.3 per share for the next quarter.
This represents a 242.86% in quarter-over-quarter growth for Meridian Bioscience, a bullish signal to many investors.
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
